9MW1911 vs astegolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: ST2 (IL1RL1) · full Chronic Obstructive Pulmonary Disease pipeline
9MW1911
Developed by Mabwell Bioscience
NCT05803902 · Phase 1 · completed
The study was randomized and blinded with a placebo comparator, but it was conducted in healthy volunteers purely to check safety and dosing rather than to test whether the drug works in patients. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse Event(including serious adverse event)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2027 · NCT07292714 (registry estimate)
Reported efficacy
Adverse Event(including serious adverse event) (Day0-Day113): Safe and well tolerated across the doses studied: most adverse events were mild to moderate and resolved without treatment, no dose-related adverse events were observed, the only serious adverse event (fetal malformation) was judged unrelated to study drug, and there were no deaths or discontinuations due to adverse events.
Result source: NCT05803902
astegolimab
Developed by Roche
NCT05595642 · Phase 3 · completed
This was a large (about 1,290 participants), randomized, double-blind, placebo-controlled trial measuring a clinically meaningful outcome (exacerbation rate), which is a strong design. However, the reported result shows only a numerical 14.5% reduction in exacerbations that did not reach statistical significance, meaning the trial did not demonstrate a clear treatment benefit despite its rigorous design.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2027 · NCT05878769 (registry estimate)
Reported efficacy
Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period (52 weeks): ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant (missed)
Result source: NCT05595642
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | 9MW1911 | astegolimab |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Not posted · NCT05595642 |
| Trough FEV1, change | —Not reported | —Not posted · NCT05595642 |
| SGRQ total, change | —Not reported | 57.7 vs 63.3−5.6 vs placeboNCT036150404 other results
|
| TDI focal score | —Not reported | —Not posted · NCT05595642 |
Moderate or severe exacerbations, annualised rate
- 9MW1911
- —Not reported
- astegolimab
- —Not posted · NCT05595642
Trough FEV1, change
- 9MW1911
- —Not reported
- astegolimab
- —Not posted · NCT05595642
SGRQ total, change
- 9MW1911
- —Not reported
- astegolimab
- 57.7 vs 63.3−5.6 vs placeboNCT03615040
4 other results
- 59.5 vs 59.5 NCT03615040
- 56.6 vs 59.6 NCT03615040
- 56.9 vs 59.9 NCT03615040
- 56.7 vs 58.9 NCT03615040
TDI focal score
- 9MW1911
- —Not reported
- astegolimab
- —Not posted · NCT05595642
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9MW1911: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. 9MW1911: 0 of 4 rows · astegolimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | astegolimab |
|---|---|
| Dropout rate | 14.3%a NCT03615040 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03615040 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 28.6%a NCT03615040 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 23.8% (placebo 12.8%) urinary tract infection 14.3% (placebo 2.6%) chest pain 11.9% (placebo 10.3%) NCT03615040 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
astegolimab
show 4 more results
show 5 more results
show 5 more results
+ 10 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 9MW1911's landscape · astegolimab's landscape